Engineered stem cell as well as preparation method and application thereof
Genetic engineering makes ADSCs express HGF highly, which solves the problems of limited efficacy and poor stability of HGF in the treatment of focal scleroderma, achieves significant anti-fibrosis and angiogenesis effects, improves treatment safety and efficiency, and reduces cost.
Patent Information
- Application Number
- CN202411344960.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-25
- Publication Date
- 2024-11-08
AI Technical Summary
The existing treatment methods for focal scleroderma have limited efficacy and many side effects, and the short half-life and poor in vivo stability of high-expression HGF limit their clinical application and it is difficult to achieve the purpose of enhancing anti-fibrosis ability through engineering ADSCs.
Through genetic engineering, fat mesenchymal stem cells (ADSCs) are highly expressed in hepatocyte growth factor (HGF), enhancing their anti-fibrosis and promoting tissue repair capabilities. Viral vectors, transfection and other methods are used to make ADSCs show anti-fibrosis. Function upregulation to form engineered stem cells.
Significantly enhance the anti-fibrosis ability of ADSCs, reduce the expression of fibrotic markers in skin fibroblasts, promote angiogenesis, improve treatment effect and safety, reduce side effects, ensure the stability of the treatment effect, and reduce production costs.
Smart Images

Figure CN118909956A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biopharmaceuticals, and in particular to an engineered stem cell and a preparation method and application thereof. Background Art
[0002] Localized scleroderma is a chronic, autoimmune disease characterized by excessive fibrosis of the skin and connective tissue, leading to skin hardening and functional impairment. Existing treatments include immunosuppressants, anti-inflammatory drugs, and physical therapy, but these methods have limited efficacy and many side effects. Adipose-derived mesenchymal stem cells (ADSCs) and the hepatocyte growth factor (HGF) they secrete provide a new treatment for localized scleroderma.
[0003] Adipose-derived stem cells (ADSCs) are a type of multipotent stem cells that are abundant and easy to obtain, and have significant immunomodulatory and tissue repair abilities. In recent years, ADSCs have shown great potential in the treatment of various fibrotic diseases. ADSCs can not only differentiate into a variety of cell types, but also secrete a variety of biologically active factors, such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), etc., which play an important role in tissue repair and anti-fibrosis. Studies have shown that ADSCs can reduce the degree of pulmonary fibrosis and liver fibrosis by secreting anti-fibrotic factors and immunomodulatory factors. In one study, ADSCs were transplanted into a silica dust-induced pulmonary fibrosis mouse model, and the results showed that ADSCs significantly reduced pulmonary fibrosis and exerted their anti-fibrotic effects by inhibiting macrophage activation and promoting myofibroblast apoptosis.
[0004] Hepatocyte Growth Factor (HGF) is a multifunctional factor secreted by mesenchymal cells with multiple biological functions such as promoting cell growth, anti-fibrosis and anti-inflammation. HGF activates multiple signaling pathways through its receptor c-Met to regulate cell proliferation, motility, differentiation and survival. Studies have shown that HGF has significant therapeutic effects in a variety of fibrotic diseases, such as liver fibrosis, pulmonary fibrosis and renal fibrosis. In a study on chronic kidney disease, recombinant HGF was injected to observe its effects on renal fibrosis and dysfunction. The results showed that HGF significantly inhibited the progression of renal fibrosis and improved renal function, showing its great potential in anti-fibrotic treatment.
[0005] Studies have shown that ADSCs were transplanted into mice with pulmonary fibrosis, and their effects on pulmonary fibrosis were evaluated by histological analysis and biochemical testing. Studies have found that ADSCs significantly reduced the degree of pulmonary fibrosis and improved the lung function of mice by secreting anti-inflammatory factors and pro-apoptotic factors (Gao J, Yuan J, et al. Adipose-derived stemcells therapy effectively attenuates PM2.5-induced lung injury. Stem Cell ResTher.). Although ADSCs show therapeutic effects in animal models, their specific mechanisms are not yet fully understood. The article does not clearly define the effective factors for disease treatment, especially the effector factors for fibrosis treatment. Therefore, it is difficult to achieve the goal of enhancing the anti-fibrosis ability of ADSCs through engineering.
[0006] Studies have shown that recombinant HGF was injected into a mouse model of chronic kidney disease, and its effects on renal fibrosis and dysfunction were studied by histological analysis, gene expression detection and functional evaluation. The results showed that HGF significantly reduced renal fibrosis and improved renal function by inhibiting fibroblast activation and collagen deposition (Mizuno S, Kurosawa T, etc. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease.). Although HGF showed good anti-fibrotic effects, its short half-life and poor in vivo stability limit its clinical application. In addition, the high cost of production and purification processes is also a challenge. The safety of long-term and high-dose use of HGF still needs further verification.
[0007] In summary, there is no effective treatment for focal scleroderma, and the existing background technology shows certain potential in the treatment of fibrotic diseases, but also has many shortcomings. Treatment through engineered ADSCs that highly express HGF is expected to overcome the shortcomings of existing methods and provide a new and efficient treatment method for scleroderma. Summary of the invention
[0008] The present invention aims to overcome the shortcomings of existing scleroderma treatment methods and provide a new method for treatment based on engineered adipose-derived mesenchymal stem cells that highly express hepatocyte growth factor (HGF). Existing treatment methods such as immunosuppressants, anti-inflammatory drugs and physical therapy, although they can relieve symptoms to a certain extent, have limited efficacy and many side effects. Adipose-derived mesenchymal stem cells (ADSCs) have become a potential treatment method due to their significant immunoregulatory and tissue repair abilities. However, the therapeutic effect of using ADSCs alone is still unsatisfactory. Therefore, through genetic engineering means, ADSCs are made to highly express HGF, thereby enhancing their ability to resist fibrosis and promote tissue repair, thereby more effectively treating scleroderma.
[0009] In one aspect, the present invention provides a method for producing engineered stem cells, the method comprising:
[0010] (1) Providing mesenchymal stem cells or their derivatives;
[0011] (2) Conditions for causing the mesenchymal stem cells or their derivatives to generate engineered stem cells that exhibit upregulated anti-fibrotic function and / or upregulated angiogenesis-promoting ability.
[0012] Preferably, the means for causing the mesenchymal stem cells or their derivatives to exhibit upregulated anti-fibrotic function and / or upregulated angiogenesis-promoting ability comprises exogenously introducing anti-fibrotic factors, such as hepatocyte growth factor (HGF), matrix metalloproteinases (MMPs), and the like.
[0013] In a preferred embodiment, the anti-fibrotic factor comprises the nucleotide sequence as shown in SEQ ID NO:1, or a factor having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity and retains HGF activity.
[0014] The engineered conditions include physical, chemical or biological methods, or a combination thereof. For example, the biological methods include the use of viral vectors, such as lentivirus, retrovirus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus, etc. For example, the chemical means include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads, etc.; lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles or liposomes, etc. For example, the physical methods include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, etc.
[0015] In a preferred embodiment, the engineered conditions include transfection, such as transient or stable transfection, electroporation, viral infection, microinjection, etc.
[0016] Preferably, the transfection reagent used is Lipofectamine 3000, and the plasmid is GV657.
[0017] Another aspect of the present invention provides an engineered stem cell comprising the nucleotide sequence shown in SEQ ID NO:1.
[0018] The stem cells are mesenchymal stem cells, which are derived from bone marrow, umbilical cord tissue, placental tissue, adipose tissue, etc., preferably from adipose tissue.
[0019] In another aspect, the present invention provides a culture comprising the engineered stem cells of the present invention, and a culture medium.
[0020] In the present invention, the culture medium that can be used for stem cell culture is known to those skilled in the art, and its non-limiting examples include α-MEM culture medium, DMEM culture medium, IMDM culture medium, Ham's F12 culture medium, RPMI1640 culture medium, and a mixed culture medium formed by any combination of the above. In certain exemplary embodiments, the culture medium is serum-free Yokohama medium.
[0021] The culture of the present invention can be formulated and administered as a biological preparation or a pharmaceutical composition. Such a pharmaceutical composition can be in any form known in the medical field, preferably an injection.
[0022] In another aspect, the present invention provides a culture supernatant, which is the supernatant of the culture of the present invention.
[0023] In certain preferred embodiments, the culture supernatant does not contain the engineered stem cells.
[0024] In certain preferred embodiments, the culture supernatant comprises a basal medium. In certain exemplary embodiments, the culture supernatant is a serum-free Yokohama medium.
[0025] The culture supernatant of the present invention can be formulated and administered as a biological preparation or a pharmaceutical composition.
[0026] On the other hand, the present invention provides a biological preparation, which comprises the above-mentioned engineered stem cells, and the biological preparation is an injection; preferably, the biological preparation also comprises a pharmaceutically acceptable carrier or excipient; preferably, the biological preparation also comprises a pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solution (for example, a balanced salt solution or physiological saline), dispersion, suspension or emulsion.
[0027] Preferably, the effective amount of the engineered stem cells is 100,000 (1×10 5 ) to 1,000,000 (1×106 ) cells.
[0028] In another aspect, the present invention provides the use of the above-mentioned biological preparation and the engineered stem cells in the preparation of a biological preparation for treating scleroderma.
[0029] Preferably, the scleroderma includes localized scleroderma and systemic sclerosis.
[0030] Preferably, the engineered stem cells achieve the purpose of treating scleroderma by cooperating with HGF and MMP1.
[0031] Preferably, the engineered stem cells achieve the purpose of treating scleroderma by reducing the expression levels of fibrosis markers including Collagen 1, Collagen 3, α-SMA and TGF-β1 of dermal fibroblasts (HDFs).
[0032] In certain preferred embodiments, the subject is a mammal, such as a human.
[0033] The technical solution of the present invention has the following beneficial effects:
[0034] The present invention uses genetic engineering to make ADSCs highly express HGF, thereby significantly enhancing their ability to resist fibrosis and promote angiogenesis, providing a new way to treat scleroderma. The specific effects and advantages are as follows:
[0035] (1) Improve treatment effect
[0036] Enhanced anti-fibrosis ability: Engineered ADSCs significantly reduced the expression levels of fibrosis markers (such as Collagen1, Collagen3, α-SMA, TGF-β1) of skin fibroblasts (HDFs) in in vitro experiments. qPCR and Western blot results showed that the expression of HDFs fibrosis markers in the engineered ADSCs treatment group was reduced by about 50% and more than 90% compared with the ordinary ADSCs group and the control group, respectively.
[0037] Promote angiogenesis: HGF secreted by engineered ADSCs significantly promoted the proliferation of endothelial cells and the formation of new blood vessels. In vitro angiogenesis experiments showed that the number of tubular structures formed in the engineered ADSCs group was more than twice that of the ordinary ADSCs group.
[0038] (2) Improve security and stability
[0039] Reduced side effects: Compared with traditional treatments (such as immunosuppressants and anti-inflammatory drugs), engineered ADSCs treatment has higher safety and significantly reduced side effects. In animal experiments, mice in the engineered ADSCs treatment group did not show obvious immune and inflammatory reactions.
[0040] Improved stability: Genetic engineering is used to make ADSCs highly express HGF, solving the problem of HGF's short half-life and poor stability in vivo. Engineered ADSCs continuously secrete HGF in vivo, ensuring the stability and durability of the therapeutic effect.
[0041] (3) Improve efficiency and reduce costs
[0042] Improve treatment efficiency: The anti-fibrosis effect of engineered ADSCs is significantly better than that of ordinary ADSCs and recombinant HGF protein. Under the same treatment conditions, the remission rate of skin fibrosis in mice in the engineered ADSCs group was more than 90%, while that in the ordinary ADSCs group and the recombinant HGF protein group was only reduced by about 45% and 25%. In addition, engineered ADSCs significantly increased the subcutaneous fat thickness of mice with focal scleroderma by about 90%.
[0043] Reduced production costs: Compared with the direct use of recombinant HGF protein, the use of engineered ADSCs as a treatment method can significantly reduce treatment costs and avoid the high-cost HGF production and purification process.
[0044] (4) Providing multi-effect synergistic treatment methods
[0045] Multi-effect synergistic effect: The various bioactive factors (such as HGF, VEGF, etc.) secreted by engineered ADSCs have synergistic effects, which can not only resist fibrosis, but also promote tissue repair and angiogenesis. At the same time, animal experiments have shown that after the injection of engineered ADSCs, the expression level of MMP1 in skin tissue increased significantly, which helps to explain the extracellular matrix in fibrotic tissue, thereby improving fibrosis and playing a synergistic anti-fibrotic role with HGF. In vivo and in vitro anti-fibrosis experiments show that the therapeutic effect of engineered ADSCs is much higher than that of the HGF recombinant protein treatment group, indicating that other cytokines secreted by ADSCs provide a multi-effect synergistic treatment method during the treatment process.
[0046] Improve patients’ quality of life: By effectively treating localized scleroderma, engineered ADSCs significantly improved patients’ skin function and quality of life, reducing pain and discomfort. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 RT-qPCR detection of HGF gene expression in engineered ADSCs transfected with HGF is shown;
[0048] Figure 2 shows The expression of the tag protein GFP in engineered ADSCs was shown;
[0049] Figure 3 The ELISA method is shown to detect the protein concentration of HGF in the culture supernatant of engineered ADSCs cells;
[0050] Figure 4 Shown is the Western blot detection of HGF protein expression in engineered ADSCs cells;
[0051] Figure 5 RT-qPCR detection of the expression of fibrosis-related genes in skin fibroblasts HDFs is shown;
[0052] Figure 6 The table shows the RT-qPCR detection of fibrosis-related proteins in skin fibroblasts HDFs;
[0053] Figure 7 The ELISA method is used to detect the content of hydroxyproline in the supernatant of HDFs cell culture;
[0054] Figure 8 It was shown that engineered ADSCs promoted HUVECs cells to generate blood vessels;
[0055] Fig. 9 The Masson staining of pathological skin fibrosis in mice with focal scleroderma before and after treatment is shown;
[0056] Fig.10 The statistical graphs of dermis thickness and fat layer thickness before and after treatment of mice with focal scleroderma are shown;
[0057] Fig.11 Inflammatory cell infiltration in mice with focal scleroderma before and after treatment is shown;
[0058] Fig.12 Shows the expression of MMP1 protein in scleroderma mice after injection of ADSCs and engineered ADSCs
[0059] Fig.13 The distribution of ADSCs and engineered ADSCs in mice is shown;
[0060] Fig.14 Shown is the survival time of ADSCs and engineered ADSCs in mice. DETAILED DESCRIPTION
[0061] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments and drawings. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation to the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.
[0062] The reagents used in the following examples are as follows:
[0063] Plasmid vector: GV657; transfection reagent: Lipofectamine 3000; cell culture reagent: Youkang serum-free medium; bleomycin: MCE, HY-17565A; DID cell membrane dye: Solebao Biotechnology Co., Ltd., D8940.
[0064] Other experimental methods were conventional methods unless otherwise specified.
[0065] Other materials and reagents used, unless otherwise specified, can be obtained from commercial sources.
[0066] Example 1 Construction of engineered ADSCs and detection of HGF expression
[0067] (1) Method and steps:
[0068] Isolation and culture of ADSCs: ADSCs were isolated from adipose tissue of healthy donors, inoculated in serum-free medium of Yokohama, cultured in a 37°C, 5% CO2 incubator, and passaged when they were 80-90% confluent.
[0069] Construction of recombinant plasmid: The HGF gene shown in SEQ ID NO: 1 was amplified using PCR technology and cloned into the GV657 plasmid vector. The HGF gene was inserted into the plasmid vector using restriction endonucleases and ligases.
[0070] Transfection of ADSCs: When ADSCs reach 80-90% confluency, use Lipofectamine 3000 to transfect the recombinant plasmid into ADSCs. The amount of plasmid per well of a six-well plate is 1-2.5ug, and the amount of Lipofectamine 3000 is 3.75-7.5uL. Replace the culture medium 6-8 hours after transfection and continue culturing for 48-72 hours.
[0071] HGF expression detection: RT-qPCR was used to detect the gene expression of the overexpression plasmid in ADSCs. RNA was collected after 24 hours and qPCR was performed to detect whether HGF was overexpressed at the gene level. The GFP green fluorescent label protein was observed by fluorescence microscopy to determine the successful transfection and translation of the plasmid. In addition, the ELISA method was used to detect the level of HGF secreted by ADSCs after transfection, and the protein expression level of HGF in ADSCs cells after transfection was detected by Western blot.
[0072] (2) Results:
[0073] RNA was extracted from transfected ADSCs and HGF gene expression was detected by RT-qPCR. In this experiment, qPCR was performed by fluorescence method and the CT value obtained by qPCR was 2 -ΔΔCT The expression level of HGF after transfection was calculated. The results showed that HGF was significantly highly expressed in ADSCs after transfection with HGF expression plasmid. Figure 1 As shown in Table 1. ADSCs: adipose-derived mesenchymal stem cells; Vector-ADSCs: ADSCs transfected with empty vector plasmid; HGF+-ADSCs: ADSCs transfected with HGF plasmid.
[0074] Table 1 Relative expression of HGF gene
[0075] Serial number ADSCs Vector-ADSCs <![CDATA[HGF + -ADSCs]]> 1 1 2.075488362 2980.159714 2 1 2.023878889 3031.241122 3 1 1.914398781 3292.598557
[0076] The HGF expression plasmid contains a GFP fluorescent tag, so the expression of GFP protein can be observed by fluorescence microscopy to determine whether the plasmid has been successfully transfected into the target cells and successfully translated. The results of fluorescence microscopy showed that the plasmid was successfully transfected and successfully translated in the cells. Figure 2 Show.
[0077] In addition, the expression of HGF protein in the supernatant of transfected cells was detected by ELISA. The results showed that the expression of HGF in the supernatant of ADSCs cells transfected with HGF expression plasmid increased significantly. Figure 3 And as shown in Table 2.
[0078] Table 2 Expression of HGF protein in cell culture supernatant
[0079] Serial number ADSCs (pg / mL) Vector-ADSCs(pg / mL) <![CDATA[HGF + -ADSCs(pg / mL)]]> 1 234 183 434 2 210 207 310 3 161 131 561 4 313 267 413
[0080] The protein expression level of HGF in ADSCs cells after transfection was detected by Western blot. The results showed that the expression level of HGF in ADSCs increased significantly after transfection of HGF expression plasmid. Figure 4 shown.
[0081] Example 2: Verification of the anti-fibrosis and angiogenesis-promoting functions of engineered ADSCs in vitro
[0082] (1) Raw material preparation:
[0083] Recombinant human HGF protein: PeproTech, catalog number 100-39H-25μg; Human umbilical vein endothelial cells (HUVECs): Wuhan Huaerna Biotechnology Co., Ltd., catalog number WN-057;
[0084] Human Dermal Fibroblasts (HDFs):
[0085] The separation method is as follows:
[0086] Skin fibroblasts are human upper eyelid fibroblasts isolated independently by our company. The isolation method is as follows:
[0087] Sample cleaning: The obtained skin samples were placed in a culture dish in a sterile environment and rinsed several times with a calcium- and magnesium-free PBS solution to remove blood and impurities.
[0088] Cutting samples: Cut the dermis into pieces of about 1-2 mm 3 of small pieces and placed them in a Petri dish.
[0089] Enzymatic treatment: Place the cut skin sample blocks into a digestion solution containing collagenase (e.g., 0.1%-0.2% collagenase solution), incubate in a 37° C., 5% CO 2 incubator for 2-4 hours, and shake gently occasionally to promote digestion of the tissue blocks.
[0090] Termination of enzymatic digestion: Add DMEM medium containing 10% fetal bovine serum to terminate trypsin digestion.
[0091] Filtration and centrifugation: The digestion solution was filtered through a 100 μm cell mesh, the filtrate was collected, and centrifuged (300 g, 5 minutes) to pellet the cells.
[0092] Resuspension and inoculation: Discard the supernatant, resuspend the cell pellet in fresh DMEM medium, and inoculate the cell suspension into a culture flask or dish.
[0093] Initial culture: Place the culture flask in a 37°C, 5% CO2 incubator. After 24 hours, replace the culture medium to remove non-adherent cells and residual tissue debris.
[0094] Cell expansion: When the cells reach 70%-80% confluence, digest the cells with 0.25% trypsin-EDTA solution and subculture. Usually, purified fibroblasts can be obtained after 2-3 subcultures.
[0095] (2) Testing indicators:
[0096] Fibrosis detection indicators: Collagen1, Collagen3, α-SMA, TGF-β1 gene and protein expression levels, hydroxyproline levels.
[0097] Angiogenesis detection index: HUVECs angiogenesis
[0098] (3) Methods and steps:
[0099] Anti-fibrosis effect detection: qPCR and Western blot were used to detect the effect of engineered ADSCs on fibrosis markers in HDFs. During the synthesis of collagen, proline is converted into hydroxyproline under the action of a specific enzyme (proline hydroxylase). Therefore, the content of hydroxyproline is often used as an indicator to measure collagen metabolism. The expression of hydroxyproline in HDFs was detected using a hydroxyproline (Hyp) detection kit.
[0100] Pro-angiogenesis detection: ADSCs and HUVECs cells carrying red fluorescent protein RFP were co-cultured at a seeding density of 1:1 in Yokohama serum-free medium and photographed under an inverted fluorescence microscope after 6 hours.
[0101] (4) Results:
[0102] Engineered ADSCs significantly reduced the expression levels of fibrosis marker genes in HDFs, and the expression levels of TGF-β1, α-SMA, Collagen1 and Collagen3 were reduced by more than 90% compared with the control group. Figure 5 As shown in Table 3. HDFs: human skin fibroblasts; HDFs+TGF-β: HDFs cells were stimulated with TGF-β to establish a scleroderma cell model; HDFs+TGF-β+ADSCs: ADSCs without gene editing were co-cultured with focal scleroderma cell model; HDFs+TGF-β+HGF: recombinant human HGF protein was added to the focal scleroderma cell model; HDFs+TGF-β+HGF+-ADSCs: engineered ADSCs with high expression of HGF were co-cultured with focal scleroderma cell model.
[0103] Table 3 Relative expression of fibrosis-related genes in skin fibroblasts HDFs
[0104] Serial number Gene HDFs HDFs+TGF-β1 HDFs+TGF-β1+ADSCs HDFs+TGF-β1+HGF <![CDATA[HDFs+TGF-β1+HGF + -ADSCs]]> 1 TGF-β 1 3.71417965 1.347064077 1.302155088 1.138267813 2 α-SMA 1 4.54056822 1.427303353 1.752666433 0.761896279 3 CollagenⅠ 1 2.505249752 2.160029226 1.822947737 0.990461961 4 CollagenⅢ 1 4.255216069 1.822238191 2.103075615 1.047996977
[0105] Engineered ADSCs significantly reduced the expression of fibrosis-related proteins in HDFs, such as Figure 6 As shown. Engineered ADSCs significantly reduced the level of hydroxyproline in the supernatant of HDFs cell culture, as shown Figure 7 And as shown in Table 4.
[0106] Table 4 Hydroxyproline content in the supernatant of HDFs cell culture under different treatment conditions
[0107]
[0108] Engineered ADSCs significantly promote HUVECs angiogenesis, such as Figure 8 HUVECs: HUVECs cells were cultured alone; HUVECs+ADSCs: HUVECs cells were co-cultured with ADSCs cells; HUVECs+HGF+-ADSCs: HUVECs cells were co-cultured with engineered ADSCs that highly expressed HGF.
[0109] Example 3: Verification of the anti-fibrotic function of engineered ADSCs in animal models
[0110] (1) Animal models:
[0111] The focal scleroderma model was established by subcutaneous injection of bleomycin in female C57BL6J mice (Speff) aged 6-8 weeks and weighing 18-20 g.
[0112] (2) Therapeutic experiments:
[0113] Recombinant HGF, ADSCs, and engineered ADSCs with high HGF expression were injected into bleomycin-induced focal scleroderma model mice, respectively.
[0114] ADSCs and engineered ADSCs were stained with the cell membrane dye DID to observe their distribution and persistence in mice.
[0115] (3) Testing indicators:
[0116] Histological analysis: The therapeutic effect of engineered ADSCs was evaluated by histological analysis and immunohistochemistry.
[0117] Safety assessment: Histological analysis is used to evaluate possible side effects and safety after transplantation, including immune response, inflammatory response, etc.
[0118] In vivo imaging: Small animal in vivo imaging was used to track the persistence and distribution of transplanted engineered ADSCs in mice.
[0119] (4) Results:
[0120] Engineered ADSCs significantly reduced the degree of skin fibrosis in mice, and fibrosis was almost completely alleviated. The thickness of the dermis and fat layer was close to that of non-fibrotic model mice. Fig. 9 , Fig.10As shown in Tables 5 and 6. Control: healthy control mice without modeling; Model: mice treated with vehicle control after subcutaneous injection of bleomycin to establish focal scleroderma model mice; ADSCs: model mice treated with traditional ADSCs, HGF: model mice treated with recombinant HGF protein; HGF + -ADSCs: Model mouse group treated with engineered ADSCs that highly express HGF.
[0121] There were no obvious side effects after the engineered ADSCs were injected into the body, no obvious inflammation was caused, and there was a certain inhibitory effect of inflammation after the injection of ADSCs, such as Fig.11 shown.
[0122] MMP1 (Matrix Metalloproteinase-1) is a member of the matrix metalloproteinase family. It plays an important role in the degradation of the extracellular matrix (ECM), mainly decomposing collagen, especially type I, type II and type III collagen. This enzyme plays an important role in the pathological environment of fibrosis. Seven days after the engineered ADSCs were injected into the body, the expression level of MMP1 in skin tissue increased significantly, such as Fig.12 shown.
[0123] Small animal in vivo imaging showed that engineered ADSCs were mainly present at the injection site 2 days after subcutaneous injection, such as Fig.13 shown.
[0124] The survival time is not affected by gene editing and is similar to that of unedited ADSCs, about 30 days. Fig.14 As shown and Table 7.
[0125] Table 5 Mouse dermis thickness
[0126]
[0127]
[0128] Table 6 Mouse fat layer thickness
[0129] Control(μm) Model(μm) ADSCs(μm) HGF(μm) <![CDATA[HGF + -ADSCs(μm)]]> 123.63 42.91 158.26 104.22 192.95 130.38 35.54 106.93 193.75 201 153.93 161.18 143.45 152.38 205.79 83.63 105.13 167.25 94.63 300.28 116.38 95.67 93.47 107.97 159.87 150.68 119.36 136.52 139.4 251 197.91 18.86 136.13 134.19 60.17 214.57 101.99 152.74 86.31 299.46 226.27 72.42 174.08 121.76 102.3 395.46 27.41 187.31 74.91 137.21 366.87 85.11 170.4 106.97 141.83 330.32 55.79 137.59 122.48 155.44 147.66 42.57 101.68 187.81 202.95 106.49 56.68 156.12 112.3 229.01 150.46 83.51 189.93 64.01 150.75 114.14 54.99 161.54 37.01 151.4 203.7 105.23 159.38 175.62 249.15 146.16 43.89 54.14 116.6 206.47
[0130] Table 7 Relative fluorescence intensity values of ADSCs and engineered ADSCs in vivo distribution
[0131]
[0132] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements may be made thereto based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. A method for producing engineered stem cells, the method comprising: (1) Providing mesenchymal stem cells or their derivatives; and (2) conditions for causing the mesenchymal stem cells or their derivatives to produce engineered cells that exhibit upregulated anti-fibrotic function and upregulated angiogenesis-promoting ability; The means for causing the mesenchymal stem cells or their derivatives to exhibit upregulated anti-fibrotic function and / or upregulated angiogenesis-promoting ability includes introducing exogenous anti-fibrotic factors HGF and / or MMPs.
2. The method according to claim 1, characterized in that The anti-fibrotic factor comprises the nucleotide sequence as shown in SEQ ID NO: 1, or a factor having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto and retains HGF activity.
3. The method according to claim 1, characterized in that: The engineered conditions include transfection.
4. An engineered stem cell, characterized in that: It comprises an exogenously introduced nucleotide sequence as shown in SEQ ID NO:
1.
5. The engineered stem cell according to claim 4, characterized in that The stem cells are mesenchymal stem cells, which are derived from bone marrow, umbilical cord tissue, placental tissue, and adipose tissue.
6. A biological agent, characterized in that: It comprises the engineered stem cells according to claim 4 or 5, and the biological preparation is an injection; preferably, the biological preparation also comprises a pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solution, dispersion, suspension or emulsion.
7. The biological agent according to claim 6, characterized in that The effective amount of the engineered stem cells is 1×10 5 Up to 1×10 6 within the range of cells.
8. Use of the engineered stem cells according to claim 4 or 5, or the biological preparation according to claim 6 or 7 in the preparation of a drug for treating scleroderma.
9. The use according to claim 8, characterized in that: The engineered stem cells achieve the purpose of treating scleroderma by cooperating with HGF and MMP1.
10. The use according to claim 9, characterized in that: The engineered stem cells achieve the purpose of treating scleroderma by reducing the expression levels of fibrosis markers of skin fibroblasts, including Collagen 1, Collagen 3, α-SMA and TGF-β1.
